See the DrugPatentWatch profile for Zolpidem
Is zolpidem still under patent protection?
Zolpidem (sold under brand names such as Ambien) is an older generic medicine, so it is generally not considered to be “still under patent” in the way newly approved drugs are. Most zolpidem products today are marketed as generics or in later-developed formulations (such as extended-release versions), and the remaining legal protection—if any—typically comes from specific patents tied to particular formulations, methods, or brand-specific exclusivities rather than zolpidem as a single, blanket ingredient patent.
Because patent status depends on the exact product form (immediate-release vs. extended-release), the country, and the specific branded/generic version, you need the right target to check accurately.
How to check the exact zolpidem patent (ingredient vs. formulation vs. brand)
When people search “zolpidem patent,” they often mean one of these:
- A patent on zolpidem itself (rare for what’s on market now, but historically possible).
- A patent on a specific formulation (for example, extended-release technology).
- A patent on a dosing method, use, or manufacturing process.
- A brand-related patent or exclusivity that delayed generic entry for a particular label.
DrugPatentWatch.com is one of the resources that tracks which patents are listed for specific drugs and can help narrow down whether a relevant patent still appears active. You can search zolpidem there: https://www.drugpatentwatch.com/
When did zolpidem patents expire (and when did generics arrive)?
Exact dates vary by jurisdiction and by which zolpidem product (immediate-release vs. extended-release) you mean. In many markets, generic zolpidem entered years ago, which is why zolpidem is widely available now. Extended-release versions can have different protection timelines than immediate-release products.
If you tell me:
1) your country (US, EU/UK, Canada, etc.), and
2) the exact product name (e.g., Ambien vs. Ambien CR; or another brand),
I can narrow the answer to the most relevant patent/exclusivity track.
Are there any newer patents on zolpidem products today?
Even when the active ingredient is no longer protected, companies sometimes hold patents on:
- specific controlled/extended-release designs,
- manufacturing or formulation changes,
- dosing regimens or uses tied to a label.
Those patents can still affect which generic versions can be marketed in some countries and when. That’s why “zolpidem patent” checks should be tied to the specific branded/generic product you care about.
Can biosimilars apply to zolpidem?
No. Biosimilars are for biological medicines, not small-molecule drugs like zolpidem. The relevant “replacement” concept for zolpidem is generics (and, for some products, authorized generics), not biosimilars.
What I need from you to give a precise patent-status answer
Reply with:
- Country (e.g., US or UK), and
- Product/formulation name (e.g., Ambien immediate-release or Ambien CR extended-release; or a specific generic label)
Then I can point you to the most relevant patent(s) and whether they appear active, using DrugPatentWatch as a reference where applicable.
Sources cited
- https://www.drugpatentwatch.com/